Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-01T21:15:51.118Z Has data issue: false hasContentIssue false

Chapter 18 - Immunotherapy/IVIG, Prednisolone and Intralipid in IVF

Published online by Cambridge University Press:  07 January 2019

Gabor Kovacs
Affiliation:
Monash IVF, Victoria
Lois Salamonsen
Affiliation:
Monash University, Victoria
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Macklon, NS, Geraedts, JP, Fauser, BC. Conception to ongoing pregnancy: the ‘black box’ of early pregnancy loss. Hum Reprod Update 2002; 8: 333–43.CrossRefGoogle ScholarPubMed
Christiansen, OB, Nielsen, HS, Kolte, AM. Future directions of failed implantation and recurrent miscarriage research. Reprod BioMed Online 2006; 13: 7183.Google Scholar
Sacks, G, Yang, Y, Gowen, E et al. Detailed analysis of peripheral blood natural killer cells in women with repeated IVF failure. Am J Reprod Immunol 2012; 67: 434–42.CrossRefGoogle ScholarPubMed
Egerup, P, Lindschou, J Gluud, C, Christiansen, OB. ImmuREM IPD study group. The effects of intravenous immunoglobulins in women with recurrent miscarriages: A systematic review of randomized trials with meta-analyses and trial sequential analyses including individual patient data. PLoS ONE 2015: 10: e141588.Google Scholar
De Placido, G, Zullo, F, Mollo, A et al. Intravenous immunoglobulin (IVIG) in the prevention of implantation failure. Ann N Y Acad Sci 1994, 734: 232–4.CrossRefGoogle Scholar
Sher, G, Maassarani, G, Zouves, C et al. The use of combined heparin/aspirin and immunoglobulin G therapy in the treatment of in vitro fertilization patients with antithyroid antibodies. Am J Reprod Immunol 1998; 39: 223–4.CrossRefGoogle ScholarPubMed
Stephenson, MD, Fluker, MR. Treatment of unexplained in vitro fertilization failures with intravenous immunoglobulins: A randomized, placebo-controlled Canadian trial. Fertil Steril 2000; 74: 1108–13.CrossRefGoogle ScholarPubMed
Clark, DA, Coulam, CB, Stricker, RB. Is intravenous immunoglobulin (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF). J Assist Reprod Genet 2006; 23: 113.CrossRefGoogle ScholarPubMed
Virro, MR, Winger, EE, Reed, JL. Intravenous immunoglobulin for repeated IVF failure and unexplained infertility. Am J Reprod immunol 2012; 68: 218–25.CrossRefGoogle ScholarPubMed
Meldrum, DR, Silverberg, KM, Bustillo, M, Stokes, L. Success rate with repeated cycles of in vitro fertilization-embryo transfer. Fertil Steril 1998; 69: 1005–9.Google Scholar
Nyborg, KM, Kolte, AM, Larsen, EC, Christiansen, OB. Immunomodulatory treatment with intravenous immunoglobulin and prednisone in patients with recurrent miscarriage and implantation failure after in vitro fertilization or intracytoplasmatic sperm injection. Fertil Steril 2014, 102: 1650–5.CrossRefGoogle ScholarPubMed
Li, J, Chen, Y, Liu, C, Hu, Y, Li, L. Intravenous immunoglobulin treatment for repeated IVF/ICSI failure and unexplained infertility: A systematic review and a meta-analysis. Am J Reprod Immunol 2013; 70: 434–47.Google Scholar
Moraru, M, Carbone, J, Alecsandru, D, Castillo-Rama, M et al. Intravenous immunoglobulin treatment increased live birth rate in a Spanish cohort of women with recurrent reproductive failure and expanded CD56+ cells. Am J Reprod Immunol 2012; 68: 7584.Google Scholar
Winger, EE, Reed, JL, Ashoush, S et al. Elevated preconception CD56+16+ and/or Th1: Th2levels predict benefit from IVIG therapy in subfertile women undergoing IVF. Am J Reprod Immunol 2011; 66: 394403.CrossRefGoogle ScholarPubMed
Heilmann, L, Schorsch, M, Hahn, T. CD3-CD56+CD16+ natural killer cells and improvement of pregnancy outcome in IVF/ICSI failure after additional IvIg treatment. Am J Reprod Immunol 2010; 63: 263–65.Google Scholar
Chernyshov, VP, Dons´koi, BV, Sudoma, IO, Goncharova, YO. Multiple immune deviations predictive for IVF failure as possible markers for IVIG therapy. Immunol Letters 2016; 176: 4450.Google Scholar
Coulam, CB, Goodman, C, Roussev, RG, Thomason, EJ, Beaman, KD. Systemic CD56+ cells can predict pregnancy outcome. Am J Reprod Immunol 1995; 33: 4045.CrossRefGoogle ScholarPubMed
Boomsma, CM, Keay, SD, Macklon, NS. Peri-implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database Syst Rev 2012; 6: CD005996.Google Scholar
Laskin, CA, Bombardier, C, Hannah, ME et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. New Eng J Med 1997; 337: 148–53.CrossRefGoogle ScholarPubMed
Tang, A-W, Alfirevic, Z, Turner, MA et al. A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant. Hum Reprod 2013; 28: 1743–52.CrossRefGoogle ScholarPubMed
Robertson, SA, Jin, M, Yu, D et al. Corticoid therapy in assisted reproduction-immune suppression is a faulty premise. Hum Reprod 2016; 31: 2164–73.CrossRefGoogle Scholar
Roussev, RG, Acacio, B, Ng, SC, Coulam, CB. Duration of intralipid’s suppressive effect on NK cell’s functional activity. Am J Reprod immunol 2008; 60: 258–63.CrossRefGoogle ScholarPubMed
Shreeve, N, Sadek, K. Intralipid therapy for recurrent implantation failure: new hope or false dawn? J Reprod Immunol 2012; 93: 3840.CrossRefGoogle ScholarPubMed
Coulam, CB, Acacio, B. Does immunotherapy for treatment of reproductive failure enhance live births? Am J Reprod Immunol 2012; 67: 296303.CrossRefGoogle ScholarPubMed
Meng, L, Lin, J, Chen, L et al. Effectiveness and potential mechanisms of intralipid in treating recurrent spontaneous abortion. Arch Gynecol Obstet 2016; 294: 2939.CrossRefGoogle ScholarPubMed
Check, JH, Check, DH. Intravenous intralipid therapy is not beneficial in having a live delivery in women aged 40–42 years with a previous history of miscarriage or failure to conceive despite embryo transfer undergoing in vitro fertilization-embryo transfer. Clin Exp Obstet Gynecol 2016; 43: 14–5.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×